Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Unusually-High Trading Volume – Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares saw unusually-strong trading volume on Monday . 2,413,917 shares were traded during mid-day trading, an increase of 94% from the previous session’s volume of 1,244,418 shares.The stock last traded at $14.2135 and had previously closed at $14.44.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BAYRY. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 1.7%

The company has a market cap of $55.79 billion, a P/E ratio of -27.83, a P/E/G ratio of 4.52 and a beta of 0.55. The business has a fifty day simple moving average of $12.64 and a 200 day simple moving average of $12.13. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.The business had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts anticipate that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.